Crystal Mackall and Carl June discussed groundbreaking strategies to enhance CAR T-cell therapies, pushing the boundaries for solid cancer treatment on day 3 of #AACRIO25. Learn more on the #AACRBlog: https://t.co/rTTAK8h6zk @parkerici @PennMedicine

Thrilled to share our new paper in @NatureMedicine! We analyzed 783 patients (2,200+ patient-years) receiving lentiviral or gammaretroviral T cell therapies and found no evidence of high-level insertional mutagenesis.

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

A team at @Penn, led by PICI Investigator @JoeFraietta, PhD, including @EJohnWherry, PhD, Co-Director of the PICI Center at Penn, & 2022 Parker Bridge Fellow @EvanWeberPhD, made a breakthrough in understanding TET2's role in T cell exhaustion: https://t.co/Qc2EtluO6j (1/3)

I am excited to join storied biotech pioneer @Amgen as Chief Scientific Officer and Head of Research. I look forward to partnering with my new colleagues to deepen understanding of biology and develop solutions to the most pressing medical challenges

“Howard really models kindness that you want to see in a leader, and we all benefit from that.” – postdoc Roman Reggiardo on what it’s like working in Howard Chang’s lab at @Stanford

Today #CancerGrandChallenges team eDyNAmiC and their international collaborators published 3️⃣ papers in @Nature 📣 They show the prevalence of ecDNA in cancer, identify fundamental mechanisms and an actionable target now being tested in the clinic. More: https://t.co/lx5dtVlyDK

Carl June awarded The Abarca Prize, says "Our journey is far from over, the fight against cancer is a marathon." Here congratulated by the King of Spain @AbarcaPrize #celltherapy #genetherapy #immunotherapy

Very pleased to share our new online pre-print! We explore the spatial-temporal evolution of extrachromosomal DNA (ecDNA) in human glioblastoma. https://t.co/hhseGFYZPD. A 🧵

🎉 Congrats to HHMI Investigator Howard Chang of @Stanford, one of three 2024 Albany Prize winners recognized for breakthroughs in RNA science. Chang was honored for discovering long noncoding RNA and its role in the body’s response to infection. 👏 https://t.co/uw654JzRrG ✨

Thank you for the warm welcome! I am beyond excited to join the @ImmunologyDuke team at @DukeMedSchool! Immensely grateful for the huge community of collaborators, mentors, friends and family whose support was integral to achieving this career milestone. Now the fun begins!

Enhancing genome editing of T cells expressing synthetic antigen receptors ft. @wellhausrn, Nils Engel, Caitlin Hopkins, January Salas-McKee, @AdhamBear, @SangyaAgarwal, Julie Jadlowsky, Gerald Linette, @GillSaar, @carlhjune, @JoeFraietta & @NathanSinghLab https://t.co/vjAocsjkib

A new @NEJMEvidence study found racial disparities among patients treated with #CARTcelltherapy for #lymphoma. @PennCancer's @MarcoRuella & @GuerraViswanath are trying to find why these disparities exist to ensure all patients can benefit. @PhillyInquirer

Looking for the most effective ways to CRISPR edit human T cells? Look no further! Along with the team @Penn we identified the engineering steps that control product function. Nearly 10 years of troubleshooting with Cas9 and novel base editors distilled down into 4 figures! (1/4)

@HHMINEWS @FNIH_Org I am grateful and very honored for this recognition. Many thanks to my collaborators, trainees, and mentors for their wisdom and support.

Carl June and Michel Sadelain are the Qs who supplied a secret agent – the CAR T cell – with the technology to liquidate cancers. They will be honored at the Breakthrough Prize ceremony. Watch the worldwide premiere April 21 — streaming here and at https://t.co/iwV1VOV6oc.

Twitter fam! We are looking for a research associate to join our awesome team. If you know anyone interested in the interface of protein engineering, structural bio, gene editing and T cell immunotherapy please reach out! Also, please retweet and spread the word!

Thank you @scientia_social for highlighting our work in this outreach article! @carlhjune #CARTcelltherapy

New study in @PNASNews from @CarlHJune, MD, Center Director for PICI Center @PennMedicine, and team reveals TP53 isoform Δ133p53α bolsters T cell fitness & reinvigorated CAR T cells from #CLL patients who previously didn't respond. https://t.co/nFu1E3eRDR #immunotherapy #leukemia

Thank you @rolandschelker & Luca Gattinoni for this beautiful summary! @ImmunityCP https://t.co/srqVXfXeyZ…

Editing CAR T cells to improve their functionality. Read our summary here => https://t.co/xsi9LHdDEz  @Penn_CBIO